Advanced Echocardiographic Evaluation in Liver Transplant Candidates: From Pathophysiological Insights to Precision Perioperative Management

Luigi Tritapepe¹, Laura Cascarano, Marta Iaconi, Marco Cinicola, Cristina Dantimi, Maria Vittoria Antonica, Giulia De Fazio, Manuel Delli Compagni, Micaela Maritti

¹Anesthesia and Intensive Care, San Camillo-Forlanini Hospital, Rome, Italy

---

Abstract

End-stage liver disease (ESLD) induces a profound remodeling of the cardiovascular system, leading to a state of chronic hyperdynamic circulation and latent myocardial dysfunction known as cirrhotic cardiomyopathy (CCM). As liver transplantation (LT) remains the definitive treatment for ESLD, the perioperative period presents extreme hemodynamic challenges, including the “reperfusion syndrome” and massive fluid shifts. This paper explores the critical role of advanced echocardiography—moving beyond traditional ejection fraction toward deformation imaging (2D-Speckle Tracking) and intraoperative transesophageal monitoring—as the cornerstone for risk stratification and real-time hemodynamic optimization.

---

Introduction: The Heart-Liver Axis in the Modern Era

The clinical paradigm of liver transplantation has shifted from a focus on surgical technique to a comprehensive management of systemic multi-organ failure¹. In the context of cirrhosis, the heart is not merely a bystander but a primary determinant of survival. Cardiovascular complications are responsible for approximately 7% to 21% of deaths following LT, with a prevalence of cardiac adverse events affecting up to 50% of recipients².

The physiological stress of orthotopic liver transplantation (OLT) is unparalleled in major surgery. It involves the total clamping of the inferior vena cava, profound metabolic acidosis, massive blood loss, and the sudden release of cold, acidotic, and potassium-rich blood from the graft during reperfusion. Consequently, preoperative echocardiographic assessment has evolved from a simple morphology check to a sophisticated functional phenotyping tool³. This review aims to dissect the pathophysiology of the “cirrhotic heart” and provide a technical guide to advanced echocardiographic assessment in the transplant candidate.

Pathophysiology: The “Perfect Storm” of Cirrhotic Hemodynamics

The hemodynamic hallmark of cirrhosis is portal hypertension, which triggers a cascade of neurohumoral and vascular changes^{1, 2}.

The Vasodilatory Hypothesis and Nitric Oxide Overproduction

Portal hypertension leads to the shunting of blood into the systemic circulation and the overproduction of vasodilators, primarily Nitric Oxide (NO), carbon monoxide (CO), and endogenous cannabinoids. These substances cause a profound decrease in Systemic Vascular Resistance (SVR)^{3, 4}. This vasodilation is most pronounced in the splanchnic bed, leading to a “pooling” of blood that reduces the effective circulating volume.

Adrenergic Desensitization and Chronotropic Incompetence

The heart compensates for low SVR by increasing stroke volume and heart rate, leading to a chronic hyperdynamic state⁵. However, chronic exposure to high levels of norepinephrine leads to downregulation of beta-adrenergic receptors and alteration in G-protein signaling^{1, 5}. This “blunted” response means that during the acute stress of transplant surgery, the heart may fail to mount an appropriate increase in contractility, leading to sudden cardiovascular collapse.

Structural Remodeling and Fibrosis

Chronic activation of the Renin-Angiotensin-Aldosterone System (RAAS) leads to myocardial collagen deposition. This fibrosis, coupled with subendocardial edema, increases ventricular stiffness, which is the cornerstone of diastolic dysfunction³. This stiffening makes the heart highly sensitive to the sudden volume shifts characteristic of the transplant procedure.

Cirrhotic Cardiomyopathy (CCM): Redefining Functional Assessment

For decades, CCM was masked by the “protective” effect of low afterload⁶. In 2019, the Cirrhotic Cardiomyopathy Consortium (CCC) provided a rigorous diagnostic framework⁷.

Systolic Failure and the 2D-Speckle Tracking (2D-STE) Paradigm

Traditional Left Ventricular Ejection Fraction (LVEF) is notoriously unreliable in cirrhosis. Because afterload is low, LVEF can remain > 60% even when the underlying muscle is failing.

Global Longitudinal Strain (GLS): 2D-STE tracks acoustic “speckles” to measure fiber shortening independently of the ultrasound beam angle⁸. A GLS absolute value < 18% is now the recognized threshold for systolic CCM⁹, aligning strictly with the Cirrhotic Cardiomyopathy Consortium (CCC) guidelines and joint ASE/EACVI recommendations^{8, 10}. To make these advanced metrics clinically actionable, mitigating inter-observer variability is paramount. This requires maintaining identical operators for serial preoperative evaluations or utilizing highly standardized, vendor-independent automated machine learning tools.

Strain Rate and Torsion: Emerging research suggests that assessing the “twist” and “untwist” (torsion) of the heart provides even earlier clues to myocardial fragility. A reduced untwisting rate is a precursor to overt diastolic failure.

The Strain Paradox: Interestingly, an excessively hyperdynamic GLS (> 22%) paradoxically correlates with higher post-transplant mortality⁸. Beyond being purely afterload-related, this hyperdynamic state serves as a marker of occult energetic failure and high-output stress. These exhausted hearts have reached their operational ceiling and fail abruptly when facing the sudden afterload surge during the post-reperfusion phase.

The comparative clinical capabilities of traditional versus advanced imaging are synthesized below in Table 1.

Table 1: Traditional LVEF Assessment vs. Advanced Precision Echocardiography

Parameter	Traditional LVEF	Advanced 2D-STE / GLS
Sensitivity for CCM	Low (misses subclinical dysfunction)	High (detects early myocardial deformation)
Afterload dependence	High (falsely elevated in cirrhosis)	Low (afterload-independent measurement)
Threshold	EF < 50% (conventional)	GLS < 18% (CCC 2019 criteria)
Inter-observer variability	Moderate	Reduced with AI-assisted platforms
Intraoperative use	Limited	Real-time TEE guidance feasible
Strain Paradox detection	Not applicable	GLS > 22% identifies occult energetic failure

Pulmonary Complications: PoPH and HPS

Two distinct pulmonary vascular syndromes—portopulmonary hypertension (PoPH) and hepatopulmonary syndrome (HPS)—can coexist and complicate the pre-transplant assessment. Their differentiation is critical as their hemodynamic profiles and management strategies are diametrically opposed.

Table 2: Echocardiographic Differentiation: Portopulmonary Hypertension (PoPH) vs. Hepatopulmonary Syndrome (HPS).

Feature	PoPH	HPS
Mechanism	Pulmonary vasoconstriction & remodeling	Intrapulmonary vasodilation & shunting
RV appearance	Dilated, hypertrophied	Normal or mildly enlarged
RVSP (TRV)	Elevated (>35 mmHg)	Normal or low
Bubble test (agitated saline)	Negative (no shunt)	Positive (delayed bubbles in LA)
Oxygen response	Minimal improvement	Improves with 100% O2
LT candidacy impact	Contraindication if severe (mPAP >45)	Indication for priority listing (PaO2 <60)
Post-LT course	May persist or worsen initially	Typically resolves within 12 months

Dynamic LVOTO: A Hidden Intraoperative Emergency

Dynamic Left Ventricular Outflow Tract Obstruction (LVOTO) is a critical, potentially fatal complication that can occur intraoperatively, often misdiagnosed as distributive shock.

Diagnosis: Continuous-wave Doppler reveals a “dagger-shaped” late-peaking jet with a gradient > 30 mmHg^{2, 14}.

Incidence and Risk Factors: Dynamic LVOTO occurs in approximately 1–5% of high-risk liver transplant cohorts^{17, 18}. Predisposing factors include asymmetric septal hypertrophy, severe hypovolemia, and exaggerated hypercontractility driven by exogenous catecholamines.

Stepwise Management Algorithm: LVOTO-induced shock must be managed through a strict stepwise protocol¹⁹:

1. Discontinue all active inotropic agents (e.g., epinephrine, dobutamine) immediately.
2. Administer rapid volume expansion to increase ventricular preload and cavity size.
3. Utilize pure vasoconstrictors (e.g., phenylephrine) to increase afterload without increasing contractility.
4. Administer short-acting beta-blockers (e.g., esmolol) cautiously under continuous invasive hemodynamic monitoring only as a last resort.

The Intraoperative TEE Revolution

Transesophageal Echocardiography (TEE) has transitioned from a research tool to a mandatory monitoring modality in complex LT cases².

Phase I (Pre-Anhepatic): TEE assesses baseline function and guides fluid loading before the surgical “insult.”

Phase II (Anhepatic): Monitoring the IVC during clamping is vital. TEE identifies the need for veno-venous bypass by visualizing the degree of preload collapse⁵.

Phase III (Reperfusion): The reperfusion phase carries the highest hemodynamic risk. Post-Reperfusion Syndrome (PRS) causes a sudden drop in SVR and myocardial contractility. TEE can instantly differentiate between RV failure, air embolism, or simple vasoplegia^{2, 14}.

Precision Fluid Therapy: By measuring the Left Ventricular End-Diastolic Area (LVEDA), TEE avoids the pitfalls of CVP-guided therapy, preventing fluid overload that could congest the new liver graft.

Coronary Artery Disease (CAD) and Stress Testing Limits

As the age of transplant candidates increases, so does the prevalence of CAD.

The Inefficacy of DSE: Dobutamine Stress Echocardiography (DSE) often yields false negatives in cirrhotics because they cannot achieve the target heart rate due to chronotropic incompetence or beta-blocker therapy¹⁷.

Alternative Imaging: In high-risk patients, coronary CT or invasive angiography is increasingly utilized to ensure myocardial perfusion is adequate for the transplant.

Post-Operative Considerations and Long-Term Outcomes

The impact of pre-transplant cardiac status extends far into the recovery period.

Reversibility: While some features of CCM and HPS improve after LT, PoPH may persist or even worsen initially.

The New Frontier: Point-of-Care Ultrasound (POCUS) in the ICU allows for longitudinal monitoring of cardiac recovery, ensuring the “new” cardiovascular system adapts to the normalization of SVR.

Future Perspectives: The Horizon of Cardiac Care in Liver Transplantation

Artificial Intelligence and Automated Strain Analysis

The integration of Artificial Intelligence (AI) and machine learning algorithms is poised to automate GLS measurements. AI-driven software can now perform real-time, automated segmentation of the myocardial borders, providing instantaneous and highly reproducible strain values. “Deep Learning” models trained on large datasets of transplant recipients could identify specific “strain signatures” that predict post-reperfusion syndrome or early graft failure with greater accuracy than human clinicians.

Handheld Ultrasound and POCUS in the Continuum of Care

Future perspectives include the routine use of Handheld Ultrasound (HHU) devices by the “Heart-Liver Team” across the entire perioperative continuum—from the initial outpatient clinic to the post-operative ICU. This allows for longitudinal “hemodynamic tracking,” where changes in diastolic function or RV size can be monitored daily.

3D Echocardiography and Virtual Modeling

While 2D imaging remains the standard, 3D Echocardiography offers more accurate RV assessment. “Digital Twin” technology—creating a virtual, patient-specific hemodynamic model—could allow anesthesiologists to simulate the stress of vena cava clamping and reperfusion before surgery.

Biomarker Integration and “Omics”

Identifying specific cardiac biomarkers—such as ST2 (suppression of tumorigenicity 2), Galectin-3, and selected microRNA panels (e.g., miR-122, miR-133a)—provides concrete clinical pathways to detect subclinical myocardial fibrosis and adverse outcomes in ESLD. The combination of advanced imaging and molecular profiling will move us toward “Precision Transplant Cardiology.”

Conclusion: The Integrated Heart-Liver Management

The management of the liver transplant candidate requires a multidisciplinary “Heart-Liver Team.” Advanced echocardiography—specifically 2D-STE for systolic reserve, TDI for diastolic function, and TEE for intraoperative steering—is no longer an optional luxury but a clinical mandate.

Understanding the “chameleon-like” nature of the cirrhotic heart is the key to reducing perioperative mortality and ensuring the long-term success of the life-saving gift of transplantation.

Figure 1: Flowchart of intraoperative transesophageal echocardiography (TEE) monitoring phases during orthotopic liver transplantation. Phase I (Pre-Anhepatic): baseline volumetric assessment (LVEDA) and structural screening; Phase II (Anhepatic): preload monitoring during vena cava clamping; Phase III (Reperfusion): immediate differentiation of shock etiologies (RV failure, embolism, or vasoplegia). Abbreviations: IVC, inferior vena cava; LVEDA, left ventricular end-diastolic area; LVOTO, left ventricular outflow tract obstruction; PRS, post-reperfusion syndrome; RV, right ventricle.

Acknowledgements: None

Conflicts of interest: The authors report no relevant conflicts of interest

References

1. Dourakis SP, Geladari E, Geladari C and Vallianou N. Cirrhotic cardiomyopathy: the interplay between liver and cardiac muscle. Curr Cardiol Rev. 2021;17(1):78–84.
2. Han S, Park J, Hong SH et al. Cardiovascular manifestation of end-stage liver disease and perioperative echocardiography for liver transplantation: anesthesiologist's view. Anesth Pain Med (Seoul). 2022;17(2):132–144.
3. Garg A, Armstrong WF. Echocardiography in liver transplant candidates. JACC Cardiovasc Imaging. 2013;6(1):105–119.
4. Wagener G, et al. Liver Anesthesiology and Critical Care Medicine. Springer, New York; 2018.
5. Mukhtar A, Lotfy A, Hussein A, Fouad E. Splanchnic and systemic circulation cross talks. Best Pract Res Clin Anaesthesiol. 2020;34(1):109–118.
6. Møller S, Danielsen KV, Wiese S et al. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol. 2019;13(5):497–505.
7. Izzy M, VanWagner LB, Lin G et al. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020;71(1):334-345.
8. Kakar P, Gubitosa G, Gerula C. Echocardiography in the liver transplant patient. Curr Cardiol Rep. 2021;23(8):110.
9. Kassab K, Doukky R. Cardiac imaging for the assessment of patients being evaluated for liver transplantation. J Nucl Cardiol. 2022;29(3):1078–1090.
10. Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.
11. Tamura Y, Tamura Y, Taniguchi Y, Atsukawa M. Current clinical understanding of portopulmonary hypertension treatment. Front Med (Lausanne). 2023;10:1142836.
12. Lai YK, Kwo PY. Portopulmonary hypertension. Clin Liver Dis. 2023;27(1):71–84.
13. Peppas S, Nagraj S, Koutsias G et al. Portopulmonary hypertension: a review of the current literature. Heart Lung Circ. 2022;31(9):1191–1202.
14. Bozbas SS, Bozbas H. Portopulmonary hypertension in liver transplant candidates. World J Gastroenterol. 2016;22(6):2024–2029.
15. Thomas C, Glinskii V, de Jesus Perez V, Sahay S. Portopulmonary hypertension: from bench to bedside. Front Med (Lausanne). 2020;7:569413.
16. Gandhi KD, Taweesedt PT, Sharma M, Surani S. Hepatopulmonary syndrome: an update. World J Hepatol. 2021;13(11):1699–1706.
17. Addoumieh A, Abdallah MS, Ballout JA, et al. Clinical implications of inducible LVOTO among patients undergoing liver transplant evaluation. Am Heart J Plus. 2021;4:100026.
18. Aniskevich S, Shine TS, Feinglass NG, Stapelfeldt WH. Dynamic LVOTO during liver transplantation: the role of transesophageal echocardiography. J Cardiothorac Vasc Anesth. 2007;21:577–580.
19. Wilke TJ, Vail EA, Gold AK, et al. 2024 Clinical update in liver transplantation. J Cardiothorac Vasc Anesth. 2025;39(6):1547-1555.